Handelsavisen
prelaunch
Companies Healthcare SUDA.BO
SU
SUDA.BO BSE (India) Pharmaceuticals

Suda.Bo

$30,02
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
Op margin
6,9 %
ROE
12,1 %
Net margin
3,2 %
Debt / equity
1,30
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

SUDA.BO operates in the Pharmaceuticals industry, focusing on the development and commercialization of pharmaceutical products, and generates revenue primarily through the sale of these products to healthcare providers and consumers.

Business. SUDA.BO operates in the Pharmaceuticals industry, focusing on the development and commercialization of pharmaceutical products, and generates revenue primarily through the sale of these products to healthcare providers and consumers.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
12,1 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning SUDA.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to SUDA.BO. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    SUDA.BO operates in the Pharmaceuticals industry, focusing on the development and commercialization of pharmaceutical products, and generates revenue primarily through the sale of these products to healthcare providers and consumers.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    AI synthesis
    GENERATED

    SUDA.BO exhibits a debt-to-equity ratio of 1.3, indicating a moderate reliance on debt financing relative to equity. The company's liquidity position is assessed as medium, with a current ratio of 1.29, suggesting it can cover its short-term obligations but with limited buffer. Free cash flow stands at INR 184.66 million, which is a positive sign for operational efficiency and financial flexibility.

    In terms of profitability, SUDA.BO reports a return on equity (ROE) of 12.13%, which is a strong indicator of how effectively the company is using shareholders' equity to generate profits. However, the return on assets (ROA) of 3.96% is relatively modest, suggesting that the company may not be utilizing its assets as efficiently as it could be. These metrics should be compared against the industry median to determine if SUDA.BO is outperforming or underperforming its peers.

    The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no significant geographic diversification reported. This concentration could pose a risk if the segment faces regulatory or market challenges. The lack of geographic diversification may also limit the company's ability to mitigate regional economic downturns.

    Looking at the growth trajectory, SUDA.BO's recent financial performance shows a stable revenue trend, with no significant year-over-year changes reported. The company's capital expenditure is minimal, at INR -5.86 million, indicating a conservative approach to reinvestment. This may suggest a focus on maintaining current operations rather than aggressive expansion.

    The risk assessment for SUDA.BO highlights a medium liquidity risk, primarily due to the company's current ratio and the negative net cash position after accounting for total debt. The dilution risk is assessed as low, with no significant dilution potential identified in the basic shares outstanding. However, the company's reliance on long-term debt, which amounts to INR 1.71 billion, could pose a challenge if interest rates rise or if the company's credit rating is downgraded.

    Recent events, as disclosed in the company's filings, include a focus on cost optimization and operational efficiency. The company has not reported any major new product launches or strategic acquisitions in the latest financial period. The absence of significant new developments may indicate a period of consolidation or a strategic pause in expansion efforts.

    Key takeaways
    • SUDA.BO has a strong ROE of 12.13%, indicating effective use of shareholders' equity.
    • The company's liquidity position is moderate, with a current ratio of 1.29.
    • Revenue is concentrated in a single business segment, posing potential operational risk.
    • Capital expenditure is minimal, suggesting a conservative reinvestment strategy.
    • The company's debt-to-equity ratio of 1.3 indicates a moderate reliance on debt financing.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $30,02
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $1.31B
    Net cash
    -$1.70B
    Current ratio
    1.3
    Debt / equity
    1.3
    ROA
    4.0%
    ROE
    12.1%
    Cash conversion
    221.0%
    CapEx / revenue
    -0.1%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin6,9 %Above median
    Net Margin3,2 %Below median
    ROE12,1 %Above P75
    Capex / Rev-0,1 %Above P75
    D/E1,30Bottom quartile
    Cash Conv2,21Above P75

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • SUDA.BO Market data — financials · 2026-05-29

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    SUDA.BOCanonical
    BSE (India) · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage